Developing a vaccine for Staphylococcus aureus
Task V28: Process Development and Master Bank Production for a Staph aureus Vaccine Candidate
This study is working on creating a new vaccine to help protect people from Staphylococcus aureus infections, which can be tough to treat because the bacteria resist many antibiotics, and it aims to make this vaccine safe and effective for future use.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project ID | NIH-10475959 on NIH RePORTER |
What this research studies
This research focuses on the development and production of a vaccine candidate for Staphylococcus aureus, a significant infectious disease. The project involves planning, optimizing, and manufacturing the vaccine in compliance with regulatory standards for clinical trials. Patients may benefit from the eventual availability of a vaccine that could prevent infections caused by this bacteria, which is known for its resistance to many antibiotics. The research includes thorough assessments and audits to ensure the vaccine meets safety and efficacy standards.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for Staphylococcus aureus infections, including those with weakened immune systems or chronic health conditions.
Not a fit: Patients who are not at risk for Staphylococcus aureus infections or those who have already been vaccinated against it may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of Staphylococcus aureus infections.
How similar studies have performed: Other research has shown success in developing vaccines for various infectious diseases, indicating a promising potential for this approach.
Where this research is happening
Dessau-Rosslau, Germany
- Idt Biologika Gmbh — Dessau-Rosslau, Germany (Active)
Researchers
- Principal investigator: Neubert, Andreas — Idt Biologika Gmbh
- Study coordinator: Neubert, Andreas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.